Evidence map›Paper›PMID 25061922›Full record

ArticleEpidemiology (Cambridge, Mass.)2014

Regression discontinuity designs in epidemiology: causal inference without randomized trials.

Jacob Bor, Ellen Moscoe, Portia Mutevedzi, Marie-Louise Newell, Till Bärnighausen

Abstract read
In one paragraph

Article in Epidemiology (Cambridge, Mass.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 139 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
139citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

139 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Observational

79 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Jacob BorFrom the aDepartment of Global Health, Boston University School of Public Health, Boston, MA; bAfrica Centre for Health and Population Studies, Somkhele, South Africa; cDepartment of Global Health and Population, Harvard School of Public Health, Boston, MA; and dFaculty of Medicine, University of Southampton, Southampton, United Kingdom.
Ellen Moscoe
Portia Mutevedzi
Marie-Louise Newell
Till Bärnighausen

Funding

Impact of Antiretroviral Therapy on HIV Epidemic DynamicsR01MH083539 · NIMH · BROWN UNIVERSITY · PI LURIE, MARK NATHAN · 2009 to 2012
$2.2M
Understanding causal pathways of HIV acquisition and transmission: a multi-level,R01HD058482 · NICHD · UNIVERSITY OF KWAZULU-NATAL · PI BARNIGHAUSEN, TILL, TANSER, FRANK COURTENEY · 2008 to 2012
$1.2M
NICHD NIH HHS R01 HD058482NICHD NIH HHS R01 HD058482-01NIMH NIH HHS 1R01MH083539-01NIMH NIH HHS R01 MH083539Wellcome Trust 097410
6 · The paper itself

Abstract

When patients receive an intervention based on whether they score below or above some threshold value on a continuously measured random variable, the intervention will be randomly assigned for patients close to the threshold. The regression discontinuity design exploits this fact to estimate causal treatment effects. In spite of its recent proliferation in economics, the regression discontinuity design has not been widely adopted in epidemiology. We describe regression discontinuity, its implementation, and the assumptions required for causal inference. We show that regression discontinuity is generalizable to the survival and nonlinear models that are mainstays of epidemiologic analysis. We then present an application of regression discontinuity to the much-debated epidemiologic question of when to start HIV patients on antiretroviral therapy. Using data from a large South African cohort (2007-2011), we estimate the causal effect of early versus deferred treatment eligibility on mortality. Patients whose first CD4 count was just below the 200 cells/μL CD4 count threshold had a 35% lower hazard of death (hazard ratio = 0.65 [95% confidence interval = 0.45-0.94]) than patients presenting with CD4 counts just above the threshold. We close by discussing the strengths and limitations of regression discontinuity designs for epidemiology.

Indexed as

CausalityData Interpretation, StatisticalEpidemiologic Research DesignModels, StatisticalRegression AnalysisAnti-HIV AgentsCD4 Lymphocyte CountCohort StudiesDrug Administration ScheduleHIV InfectionsHumansTreatment OutcomeAnti-HIV Agents

Identifiers

PMID25061922
PMCPMC4162343

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.